MONOPAR THERAPEUTICS INC (MNPR) Stock Price, Forecast & Analysis
NASDAQ:MNPR • US61023L2079
MNPR Key Statistics, Chart & Performance
The current stock price of MNPR is 55.09 USD. In the past month the price decreased by -18.95%. In the past year, price increased by 55.67%.
MNPR Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to MNPR. When comparing the yearly performance of all stocks, MNPR turns out to be only a medium performer in the overall market: it outperformed 63.04% of all stocks.
MNPR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MNPR. No worries on liquidiy or solvency for MNPR as it has an excellent financial health rating, but there are worries on the profitability.
MNPR Financial Highlights
Over the last trailing twelve months MNPR reported a non-GAAP Earnings per Share(EPS) of -3.96. The EPS decreased by -101.02% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.48% | ||
| ROE | -13.73% | ||
| Debt/Equity | 0 |
MNPR Forecast & Estimates
20 analysts have analysed MNPR and the average price target is 114.24 USD. This implies a price increase of 107.37% is expected in the next year compared to the current price of 55.09.
MNPR Ownership
MNPR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.78 | 397.113B | ||
| AMGN | AMGEN INC | 17.31 | 204.262B | ||
| GILD | GILEAD SCIENCES INC | 16.63 | 178.373B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.2 | 121.819B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.83 | 81.488B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.43 | 43.76B | ||
| INSM | INSMED INC | N/A | 31.99B | ||
| NTRA | NATERA INC | N/A | 30.068B | ||
| BIIB | BIOGEN INC | 12.59 | 27.594B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.97 | 21.685B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About MNPR
Company Profile
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
Company Info
MONOPAR THERAPEUTICS INC
1000 Skokie Blvd Ste 350
Wilmette ILLINOIS 60091 US
CEO: Chandler Robinson
Employees: 15
Phone: 18473880349
MONOPAR THERAPEUTICS INC / MNPR FAQ
What does MONOPAR THERAPEUTICS INC do?
Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. The company is headquartered in Wilmette, Illinois and currently employs 16 full-time employees. The company went IPO on 2019-12-19. The firm developing treatments for Wilson disease and novel radiopharmaceuticals for oncology. The Company’s product candidates are ALXN1840, MNPR-101, MNPR-101-Zr, MNPR-101-Lu, and MNPR-101-Ac. The Company’s Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. Its radiopharmaceutical program consists of MNPR-101, a proprietary humanized monoclonal antibody that is being developed across multiple product candidates conjugated with different radioisotopes, for the treatment of advanced solid tumors. MNPR-101-Zr is the Company’s clinical-stage radiodiagnostic imaging agent comprised of MNPR-101 conjugated to zirconium-89. MNPR-101-Lu is its clinical-stage radiotherapeutic comprised of MNPR-101 conjugated to lutetium-177. MNPR-101-Ac is late-preclinical stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
What is the stock price of MONOPAR THERAPEUTICS INC today?
The current stock price of MNPR is 55.09 USD. The price increased by 0.81% in the last trading session.
Does MNPR stock pay dividends?
MNPR does not pay a dividend.
What is the ChartMill technical and fundamental rating of MNPR stock?
MNPR has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is MNPR stock listed?
MNPR stock is listed on the Nasdaq exchange.
Can you provide the PE ratio for MNPR stock?
MONOPAR THERAPEUTICS INC (MNPR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.96).